Business Description
argenx SE
ISIN : NL0010832176
Compare
Compare
Traded in other countries / regions
ARGX.BelgiumARGX.USA0QW0.UKARGX.MexicoA1RG34.Brazil1AE.GermanyARGX.Austria IPO Date
2017-06-28Description
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 91.36 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 42.25 | |||||
| Beneish M-Score | -1.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 197.5 | |||||
| 3-Year EBITDA Growth Rate | 34.3 | |||||
| 3-Year EPS without NRI Growth Rate | 17.8 | |||||
| 3-Year FCF Growth Rate | -0.6 | |||||
| 3-Year Book Growth Rate | 29.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 52.69 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.01 | |||||
| 9-Day RSI | 66.09 | |||||
| 14-Day RSI | 64.87 | |||||
| 6-1 Month Momentum % | 49.74 | |||||
| 12-1 Month Momentum % | 13.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.53 | |||||
| Quick Ratio | 7.88 | |||||
| Cash Ratio | 6.21 | |||||
| Days Inventory | 529.38 | |||||
| Days Sales Outstanding | 81.73 | |||||
| Days Payable | 455.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.6 | |||||
| Shareholder Yield % | -0.04 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.55 | |||||
| Operating Margin % | -13.87 | |||||
| Net Margin % | -2.25 | |||||
| FCF Margin % | -25 | |||||
| ROE % | -1.11 | |||||
| ROA % | -0.99 | |||||
| ROIC % | -15.03 | |||||
| ROC (Joel Greenblatt) % | -13.52 | |||||
| ROCE % | -1.65 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 68.33 | |||||
| PS Ratio | 20.71 | |||||
| PB Ratio | 8.71 | |||||
| Price-to-Tangible-Book | 9.08 | |||||
| EV-to-EBIT | -557.09 | |||||
| EV-to-Forward-EBIT | 71.02 | |||||
| EV-to-EBITDA | -557.09 | |||||
| EV-to-Forward-EBITDA | 68.64 | |||||
| EV-to-Revenue | 18.74 | |||||
| EV-to-Forward-Revenue | 10.38 | |||||
| EV-to-FCF | -74.11 | |||||
| Price-to-Median-PS-Value | 0.51 | |||||
| Price-to-Net-Current-Asset-Value | 10.03 | |||||
| Price-to-Net-Cash | 14.57 | |||||
| Earnings Yield (Greenblatt) % | -0.18 | |||||
| FCF Yield % | -1.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
argenx SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,702.2 | ||
| EPS (TTM) (€) | -0.8 | ||
| Beta | 0.57 | ||
| Volatility % | 34.79 | ||
| 14-Day RSI | 64.87 | ||
| 14-Day ATR (€) | 9.932569 | ||
| 20-Day SMA (€) | 554.34 | ||
| 12-1 Month Momentum % | 13.07 | ||
| 52-Week Range (€) | 290.8 - 584 | ||
| Shares Outstanding (Mil) | 59.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
argenx SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
argenx SE Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
argenx SE Frequently Asked Questions
What is argenx SE(STU:1AE)'s stock price today?
The current price of STU:1AE is €578.60. The 52 week high of STU:1AE is €584.00 and 52 week low is €290.80.
When is next earnings date of argenx SE(STU:1AE)?
The next earnings date of argenx SE(STU:1AE) is 2025-02-28 Est..
Does argenx SE(STU:1AE) pay dividends? If so, how much?
argenx SE(STU:1AE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers